House Republicans are pushing a series of bills with hopes to highlight their hardline position on China and differentiate from Democrats ahead of the upcoming elections. Opposition to China has proven to be one of the most bipartisan policy stances in the 118th Congress.
The House passed 25 bills, including:
- “The No WHO Pandemic Preparedness Treaty Without Senate Approval Act,” which requires Senate approval for any World Health Organization (WHO) agreement on pandemic preparedness.
- “The End Chinese Dominance of Electric Vehicles in America Act,” which blocks electric vehicle (EV) tax credits for vehicles containing parts made or assembled by entities from China, Russia, North Korea, and Iran.
- “The Protecting American Agriculture from Foreign Adversaries Act,” which restricts ownership of U.S. farmland by citizens of China, Russia, North Korea, and Iran.
- “The DHS Restrictions on Confucius Institutes and Chinese Entities of Concern Act,” which denies Federal funds to universities who work with Chinese-backed research institutes. Representative August Pfluger (R-TX) stated that Confucious Institutes effectively conduct “widespread military espionage inside the United States.”
Though most of the proposed measures were divided along party lines, there was broad bipartisan support for “The BIOSECURE Act.” The U.S. House of Representatives passed “The
BIOSECURE Act” with a 306-81 vote. The bill aims to ban Federal contracts with Chinese biotechnology companies, including WuXi AppTec, WuXi Biologics, BGI Group, BGI-related MGI Tech, and MGI’s U.S. subsidiary Complete Genomics, citing national security concerns. The bill, which supporters argue is necessary to protect U.S. health and genetic data and secure pharmaceutical supply chains, must now pass the Senate before potentially becoming law.
Representative Jim McGovern (D-MA) opposed the bill, criticizing the lack of clarity on how companies were chosen. He stated, “In the United States of America, Congress does not just pick companies to punish at random with no clear criteria or due process.” The targeted companies expressed disappointment with the decision. BGI Group responded by saying, “We are disappointed that the U.S. legislative process is being used to pick winners and losers.” Complete Genomics added that the bill is driven by “geopolitics instead of facts” and warned it could harm U.S. leadership in biotech innovation and drug development. The Chinese Foreign Ministry criticized the U.S. move, with spokesperson Mao Ning stating, “China will continue to firmly safeguard the legitimate rights and interests of its companies.” The bill’s future in the Senate remains uncertain, as a similar measure passed the Senate Homeland Security Committee in March but has yet to reach the Senate Floor for a vote.
There was also bipartisan support for bills banning the use of Chinese-made surveillance drones and batteries, including “The Countering CCP Drones Act” and “The Decoupling From Foreign Adversarial Battery Dependence Act.” Some ambitious proposals, such as restricting outbound investments in sensitive Chinese sectors and changing import tax thresholds (de minimis rules), were not included, likely due to internal disagreements and pushback from industry groups. Additional information about the passed bills can be found in a press release published by the House Select Committee on Strategic Competition between the United States and the Chinese Communist Party which can be viewed here.
|